The regulatory mechanisms, signaling pathways, and future prospects to therapeutically target ACK in cancer have been recently reviewed (6) but ultimately, the successful development of therapeutic inhibitors to downregulate ACK signaling will rely on a detailed understanding of the pathways that lead to ACK activation and the signaling cascades that are activated downstream of ACK. The gene discussed is TNK2; the disease is cancer.